Fabian Zohren

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 2 papers. Top paper: “1834P Exposure-efficacy analyses of talazoparib in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) in the TALAPRO-2 trial”.

1834P Exposure-efficacy analyses of talazoparib in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) in the TALAPRO-2 trial

Annals of Oncology(2023)10.1016/j.annonc.2023.09.2782

N/A

0DataRank · unranked

1 citations

Victor R. Lincha, Mohammad Hadigol, Justin Hoffman, N. Agarwal, N. Matsubara +5 more

HSD3B1 genotype and outcomes in metastatic hormone-sensitive prostate cancer with androgen deprivation therapy and enzalutamide: ARCHES

Cell Reports Medicine(2024)10.1016/j.xcrm.2024.101644

N/A

0DataRank · unranked

8 citations

Arun Azad, Mona Patel, Jason W.D. Hearn, Michele Wozniak, Fabian Zohren +5 more